Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Based on the pervious data, aflibercept in combination with FOLFIRI is one of the effective
2nd line treatment option in advanced colorectal cancer. In this study, we prospectively
assess the efficacy of 2nd line aflibercept in combination with FOLFIRI in advanced
colorectal cancer in terms of progression-free survival. We further assess the efficacy
according to the type of 1st line treatment. plasma biomarker study (HGF, VEGF-A, VEGF-D,
IFN-γ, Angiopoietin-2, sICAM-1, sVCAM-1, TIMP-1, PIGF (HS), IL-6 (HS), IL-8 (HS),
sNeuropilin-1, Thrombospondin-2 , Osteopontin , sVEGFR1, sVEGFR2, sVEGFR3) , overall survival
(OS)OS, objective response rate (ORR), and safety are also assessed as the 2ndary objectives.